See more : Huuuge, Inc. (HUG.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Harrow Health, Inc. (HROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harrow Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- capsensixx AG (CPX.DE) Income Statement Analysis – Financial Results
- General Datacomm Industries Inc. (GNRD) Income Statement Analysis – Financial Results
- Centrais Elétricas Brasileiras S.A. – Eletrobrás (EBR) Income Statement Analysis – Financial Results
- Kirloskar Ferrous Industries Limited (KIRLFER.BO) Income Statement Analysis – Financial Results
- A-Mark Precious Metals, Inc. (AMRK) Income Statement Analysis – Financial Results
Harrow Health, Inc. (HROW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.harrowinc.com
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M | 41.37M | 26.77M | 19.94M | 9.72M | 1.66M | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | 9.83M | 5.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M | 4.51M | 567.41K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% | 46.42% | 34.18% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.88M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K | 332.00K | 236.66K | 1.62M | 1.30M | 111.55K | 194.59K | 2.97M | 1.99M | 1.83M | 150.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.96M | 17.57M | 12.50M | 8.09M | 5.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 430.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06M | 7.38M | 6.50M | 2.39M | 85.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -423.79K |
| SG&A | 83.09M | 58.24M | 41.32M | 31.25M | 33.10M | 29.24M | 25.02M | 24.95M | 19.00M | 10.48M | 6.08M | 2.98M | 827.67K | 2.31M | 1.60M | 1.76M | 2.86M | 6.21K |
| Other Expenses | 0.00 | -15.93M | -19.49M | -3.80M | 630.00K | 103.00K | 0.00 | 1.54M | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -110.00K |
| Operating Expenses | 90.12M | 61.29M | 52.40M | 33.66M | 35.18M | 30.07M | 25.43M | 25.69M | 19.33M | 10.71M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Cost & Expenses | 129.76M | 86.68M | 70.61M | 48.12M | 51.93M | 46.59M | 38.94M | 35.52M | 24.54M | 11.81M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Interest Income | 0.00 | 7.24M | 5.44M | 2.24M | 0.00 | 0.00 | 0.00 | 10.00K | 13.00K | 32.45K | 43.76K | 15.41K | 0.00 | 512.00 | 10.44K | 67.01K | 48.44K | 0.00 |
| Interest Expense | 21.32M | 7.24M | 5.44M | 2.24M | 2.50M | 2.73M | 3.03M | 6.00M | 1.12M | 3.80K | 0.00 | 24.66K | 75.00K | 55.48K | 0.00 | 0.00 | 1.56M | -10.00K |
| Depreciation & Amortization | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610.00K | 85.35K | 5.66K | 2.94K | 338.00 | 1.06K | 1.06K | 704.00 | 201.25K | 0.00 |
| EBITDA | 9.72M | -3.20M | -10.14M | 3.49M | 1.44M | -2.73M | -10.40M | -14.06M | -14.21M | -10.06M | -7.64M | -5.36M | -878.60K | -2.47M | -4.55M | -4.12M | -2.75M | -46.21K |
| EBITDA Ratio | 7.47% | 2.17% | 2.91% | 2.27% | 4.22% | -7.21% | -55.59% | -59.13% | -146.27% | -604.06% | -76,374.65% | -4,160.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 431.00K | -1.75M | -284.00K | -1.63M | -503.00K | -5.22M | -12.16M | -15.88M | -14.82M | -10.15M | -7.69M | -4.18M | -939.23K | -2.50M | -4.56M | -3.75M | -2.86M | -46.21K |
| Operating Income Ratio | 0.33% | -1.97% | -0.39% | -3.34% | -0.98% | -12.61% | -45.43% | -79.64% | -152.55% | -611.16% | -76,868.79% | -4,178.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -24.37M | -15.93M | -19.49M | -3.80M | 386.00K | 19.84M | -757.00K | -3.32M | -1.08M | 28.65K | 43.76K | -1.20M | -14.71K | -28.67K | 10.44K | 375.00K | -1.43M | -533.79K |
| Income Before Tax | -23.94M | -14.01M | -17.87M | -3.42M | -125.00K | 14.63M | -12.92M | -19.20M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | 0.00 | -3.37M | -2.77M | -580.00K |
| Income Before Tax Ratio | -18.39% | -15.81% | -24.66% | -6.99% | -0.24% | 35.35% | -48.26% | -96.27% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 470.00K | 75.00K | 133.00K | 4.00K | 2.47M | -19.45M | -935.00K | -111.00K | 1.08M | -28.65K | -43.76K | 1.20M | -60.29K | -26.30K | -10.44K | -817.01K | -228.27K | 10.00K |
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -2.59M | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | -4.55M | -3.30M | -4.28M | -46.21K |
| Net Income Ratio | -18.75% | -15.90% | -24.85% | -7.00% | -5.07% | 35.35% | -44.76% | -95.71% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| EPS Diluted | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| Weighted Avg Shares Out | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 23.81M | 19.98M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
| Weighted Avg Shares Out (Dil) | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
Tough Preferred Stock IPO Environment Continues: 6 December 2022 Offerings
As December 2022 comes to a close, we observe six new preferred stock / exchange-traded-debt (ETD) offerings during the month, offering annual yields ranging from 6.75% to 11.875%. Here is a comparison against the highest quality preferred stocks in our...
Harrow Health Transaction Moves It Closer To The Big Leagues For 2023
Harrow Health is a founder-led eyecare company, the CEO holds 10% of the shares. It is moving up the value chain with a focus on branded products such as a recent (second) deal with Novartis.
Harrow Health forges agreement to acquire exclusive US rights to blockbuster Novartis eyecare drugs
Harrow Health Inc (NASDAQ:HROW) revealed that it has forged a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic products from the Novartis group of companies. The Nashville, Tennessee-based...
Harrow Health, Inc. (HROW) Q3 2022 Earnings Call Transcript
Sienna Harrow Health, Inc. (NASDAQ:HROW ) Q3 2022 Earnings Conference Call November 14, 2022 4:45 PM ET Company Participants Jamie Webb – Director-Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference...
Harrow Announces Third Quarter 2022 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (NASDAQ: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced results for the third quarter ended September 30, 2022. The Company also posted its third quarter Letter...
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November...
Harrow Health, Inc.'s (HROW) CEO Mark Baum on Q2 2022 Results - Earnings Call Transcript
Harrow Health, Inc. (NASDAQ:HROW ) Q2 2022 Earnings Conference Call August 9, 2022 4:45 PM ET Company Participants Jamie Webb - Director of Communications and Investor Relations Mark Baum - Chief Executive Officer and Chairman of the Board Andrew Boll...
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for...
7 Mighty Micro-Cap Stocks That Could Be Future Moonshots
These seven micro-cap stocks, either due to catalysts or a low valuation, could make a move to substantially higher prices. The post 7 Mighty Micro-Cap Stocks That Could Be Future Moonshots appeared first on InvestorPlace.
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
Harrow began commercial operations in 2014 with no products or customers, and today is the largest U.S. ophthalmic focused pharmacy. Growth is robust, with Q1 2022 revenue up 43% YOY. Harrow entered an opaque market filled with middle men and...
Source: https://incomestatements.info
Category: Stock Reports